Ticagrelor + Clopidogrel

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Diabetes Mellitus. Type 2

Trial Timeline

Apr 1, 2015 → Feb 1, 2017

NCT ID

NCT02457130

About Ticagrelor + Clopidogrel

Ticagrelor + Clopidogrel is a approved stage product being developed by AstraZeneca for Coronary Artery Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT02457130. Target conditions include Coronary Artery Disease, Diabetes Mellitus. Type 2.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04069234	Phase 3	Withdrawn	Sep 15, 2019	Mar 31, 2022	Diabetes Mellitus
NCT03437044	Approved	Completed	Mar 14, 2018	Jun 27, 2020	Diabetes Mellitus, Type 2
NCT02617290	Phase 3	Completed	Jan 9, 2017	Sep 15, 2020	Coronary Artery Disease
NCT02663713	Approved	Completed	Jan 1, 2017	Jun 1, 2017	Myocardial Infarction
NCT02319941	Phase 2	Completed	May 20, 2015	Mar 10, 2017	Acute Coronary Syndrome
NCT02457130	Approved	UNKNOWN	Apr 1, 2015	Feb 1, 2017	Coronary Artery Disease
NCT02379676	Approved	UNKNOWN	Jan 1, 2015	Mar 1, 2017	Endothelial Dysfunction
NCT02121288	Approved	Withdrawn	Dec 1, 2014	Feb 1, 2016	Peripheral Artery Disease
NCT02233790	Approved	UNKNOWN	Dec 1, 2014	Dec 1, 2016	Myocardial Infarction
NCT02618733	Pre-clinical	Completed	Dec 1, 2014	Dec 31, 2016	Acute Coronary Syndrome
NCT02052635	Approved	Terminated	Sep 1, 2014	Apr 1, 2015	Non-ST Elevation Acute Coronary Syndrome
NCT01826175	Approved	Withdrawn	May 1, 2013	May 1, 2014	Acute Coronary Syndrome
NCT01864005	Approved	Completed	May 1, 2013	Mar 1, 2014	Non-ST or ST Elevation Acute Coronary Syndromes
NCT01732822	Phase 3	Completed	Dec 4, 2012	Sep 26, 2016	Peripheral Artery Disease
NCT01706510	Approved	Completed	Dec 1, 2012	Apr 1, 2014	Coronary Artery Disease
NCT01603082	Approved	Completed	Jul 1, 2012	Jun 1, 2014	Acute Coronary Syndrome
NCT01523366	Approved	Completed	Apr 1, 2012	May 1, 2013	Stable Coronary Artery Disease
NCT01523392	Approved	Completed	Mar 1, 2012	Sep 1, 2013	Stable Coronary Artery Disease
NCT01118325	Phase 2	Completed	Apr 1, 2010	Mar 1, 2011	Stable Coronary Artery Disease
NCT00391872	Phase 3	Completed	Oct 1, 2006	Mar 1, 2009	Acute Coronary Syndrome

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	18
Evolocumab	HeartFlow	Approved	80
High intensity lipid lowering	HeartFlow	Pre-clinical	18
Exenatide	Eli Lilly	Phase 3	77
Clopidogrel treatment group	Yuhan	Approved	85
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	77
statins, ezetimibe + Combination therapy	Yuhan	Approved	85
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	85
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	33
Prasugrel	Daiichi Sankyo	Approved	85
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	23
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	52
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	33
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	85
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	77
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved